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Abstract
Background: Angelman syndrome (AS) is a severe neurodevelopmental disorder caused by mutations affecting
UBE3A gene expression. Previous studies in mice revealed distinct critical periods during neurodevelopment in
which reactivation of Ube3a gene expression can prevent the onset of behavioral deficits. Whether UBE3A is
required for brain function throughout life is unknown. Here, we address the importance of maintaining UBE3A
expression after normal brain development.
Findings: Using a conditional mouse, we deleted the Ube3a gene at three ages spanning brain maturation. We
assessed the consequences of Ube3a gene deletion by testing the mice in behavioral tasks previously shown to
produce robust phenotypes in AS model mice. Early embryonic deletion of Ube3a recapitulated all behavioral
deficits of AS mice. In contrast, Ube3a gene deletion at 3 or 12 weeks of age did not have a significant effect on
most behavioral tasks and did not increase seizure sensitivity.
Conclusions: Taken together, these results emphasize that UBE3A critically impacts early brain development, but
plays a more limited role in adulthood. Our findings provide important considerations for upcoming clinical
trials in which UBE3A gene expression is reactivated and suggest that even transient UBE3A reinstatement
during a critical window of early development is likely to prevent most adverse Angelman syndrome
phenotypes. However, sustained UBE3A expression into adulthood is probably needed for optimal clinical benefit.
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Introduction
Loss of the maternally inherited UBE3A allele results in
Angelman syndrome (AS), a severe neurodevelopmental
disorder, which is characterized by severe intellectual dis-
ability, motor coordination deficits, absence of speech, ab-
normal EEG, and behavioral deficits [1]. UBE3A gene
dosage also appears to be critical with respect to autism
spectrum disorder (ASD) [2]. Previous studies showed that
there is up to 50% ASD comorbidity in AS individuals [3–
5], while overdosage of UBE3A, due to copy number vari-
ation of the 15q11–13 region, is among the highest genetic
risk factors for ASD, accounting for up to 0.4% of all cases
[6, 7]. Since duplication of the maternal locus is highly asso-
ciated with pathogenicity [7–10], it is likely that UBE3A
(the only maternally expressed gene in this locus) is the
major effector of ASD outcome. Indeed, duplications of just
the UBE3A gene, as well as a gain-of-function UBE3A point
mutation that renders UBE3A enzymatically hyperactive,
have been linked to severe forms of ASD [11–14].
One of the most promising approaches for developing a
treatment for AS is based on the activation of the epigeneti-
cally silenced paternal UBE3A gene. Paternal UBE3A is si-
lenced in neurons by a long non-coding UBE3A-ATS
transcript, which can be activated by either using anti-sense
oligonucleotides (ASOs) that target the degradation of this
transcript or by topoisomerase inhibitors that interfere with
the transcription of the UBE3A-ATS [15–17]. These
UBE3A reinstatement approaches are particularly attractive
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since they restore UBE3A protein levels without risking
over-expression.
Using an inducible Ube3a mouse model in which gene
expression was genetically reinstated at different time
points of brain development, we revealed distinct critical
windows during brain development in which Ube3a
needs to be reactivated to achieve an optimal behavioral
rescue [18]. This suggests that early therapeutic inter-
vention is needed for UBE3A reinstatement therapy to
be fully effective. However, these results also pose a new
question: to what extent is UBE3A expression required
after brain development and should treatment be con-
tinued after brain development has taken place?
To address this question, we made use of a conditional
mouse model for AS that enabled us to delete the Ube3a
gene at any desired time point. We found that early em-
bryonic deletion of Ube3a recapitulated phenotypes that
were previously described for AS mice [19]. In contrast,
behavioral deficits were mostly absent when the Ube3a
gene was deleted in young (3 weeks) or fully adult (12
weeks) mice. These results emphasize that most pheno-
types observed in AS mice reflect developmental deficits.
Continued UBE3A expression beyond the completion of
brain development may not be required for normal per-
formance on most behavioral tasks.
Methods
Mouse breeding
We made use of the Ube3aflox (Ube3atm1.1Bdph, MGI:58820
92) mice as previously described [20]. These mice were
maintained in the C57BL/6 J (Charles River Laboratories)
background by crossing male B6.Ube3am+/pflox mice with
C57BL/6 J females. For the behavioral experiments, we used
mice in the B6129S2F1 background, which were generated
as described below. To generate embryonic deletion of
Ube3a, B6.Ube3am+/pflox female mice were crossed with
CAG (CMV early enhancer/chicken actin promoter) CRE-
expressing male mice [MGI:2176435; Tg (CAG-cre)13Miya,
in the manuscript referred to as Creembryo] in the 129S2/
SvPasCrl background (Charles River Laboratories) [21].
This breeding yielded four experimental groups in a
B6129SF1 background: WT mice with and without CRE,
and Ube3amflox/p+ mice with and without CRE.
To allow temporal control of Ube3a deletion at 3 and
12 weeks of age, B6.Ube3am+/pflox female mice were
crossed with homozygous 129S2CreERT [MGI:2182767; Tg
(CAG-CRE/Esr1*)5Amc/J, also referred to as Tg (CAG--
CRE-ERT2)] male mice [22]. This breeding yielded two
experimental groups in a 129S2B6F1 background: WT
mice with the CAGcre/Esr1 allele and Ube3amflox/p+ mice
with the CAGcre/Esr1 allele.
For the seizure susceptibility experiments, we used
mice in the 129S2/SvPasCrl background. To that end,
B6.Ube3amflox/p+ mice were backcrossed for four to five
generations in the 129S2/SvPasCrl background. Female
129S2.Ube3am+/pflox mice were crossed with either Tg
(CAG-CRE) or CreERT male mice in the congenic 129S2/
SvPasCrl background (backcrossed > 20 generations).
Mouse husbandry
All mice were group-housed in a barrier facility, in cages
that were individually ventilated (IVC; 1145 T cages from
Techniplast). Mice were genotyped when they were 4–7
days old and re-genotyped at the completion of the ex-
periments. All animals were kept at 22 ± 2 °C with a
12-h dark and light cycle and provided with mouse chow
(801727CRM(P) from Special Dietary Service) and water
ad libitum. During behavioral testing, mice remained
group-housed, except during the nest building test and
subsequent forced swim test.
Tamoxifen treatment and randomization
Three or 12-week-old CreERT;Ube3amflox/p+ transgenic
mice and their wild type littermates (both sexes) re-
ceived tamoxifen to induce Cre-mediated deletion of the
Ube3a gene. Tamoxifen (Sigma-Aldrich) was diluted in
vegetable (sunflower) oil at a concentration of 20 mg/ml
as previously described [18, 22, 23] and as recommended
by the Jackson Laboratories [24]. For five consecutive
days, each mouse received 0.10 mg tamoxifen per gram
body weight daily by intraperitoneal (IP) injection. The
control group received daily IP injections of sunflower
oil for five consecutive days (vehicle). Injection of either
tamoxifen or vehicle was randomly assigned to the mice
and the experimenter was blind to genotype.
Behavioral test battery
All behavioral experiments were performed during the
light period of the light/dark cycle. Both male and female
mice were used at the ages indicated in the text. Mice
were acclimatized to the testing room for 30min before
each behavioral performance. All behavioral testing and
scoring were performed by an experimenter blind to geno-
type. Behavioral tests were precisely performed as previ-
ously described [18, 19] and as listed below:
Accelerating rotarod
Motor capabilities were tested by placing the mice on
the accelerating rotarod (4–40 rpm, in 5 min; model
7650, Ugo Basile Biological Research Apparatus, Varese,
Italy). Mice were tested twice per day with a 45–60-min
inter-trial interval for five consecutive days (same hour
every day). For each day, the average time spent on the
rotarod was calculated, or the time until the mouse
made three consecutive wrapping/passive rotations on
the rotarod (latency in seconds). The maximum duration
of a trial was 5 min.
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Open field test
In this test, which is useful to test locomotor activity
and anxiety, mice were individually placed in a brightly
lit 110-cm-diameter circular open field (25 lx in the mid-
dle of the arena) and allowed to explore the space for
10 min. The total distance moved by each mouse in the
open arena was recorded by an infrared camera (Noldus®
Wageningen, NL) connected to the EthoVision® software
(Noldus® Wageningen, NL), and the final outcome is in-
dicated as distance moved in centimeters.
Marble burying test
Open makrolon (polycarbonate) cages (50 × 26 × 18 cm)
were provided with 4 cm of bedding material (Lignocel®
Hygenic Animal Bedding, JRS). On top of the bedding
material, 20 blue glass marbles were placed in an equi-
distant 5 × 4 grid and the animals were free to access to
the marbles for 30 min. Once the time was run out, the
mice were gently removed from the cage. The outcome
measured is the number of buried marbles, which were
scored as buried when covered more than 50% by bed-
ding material.
Nest building test
Mice were single housed for a period of 5 to 7 days be-
fore the start of the experiment. Successively, the used
nesting material was replaced with around 11 g (11 ± 1)
of compressed extra-thick blot filter paper (Bio-rad©).
The amount of the unused nest material was weighed
and noted daily for a consecutive of 5 days, each day at
the same hour.
Forced swim test
Mice were placed in a cylindrical transparent tank (27
cm high and 18 cm diameter), filled with water (26 ± 1 °
C) 15 cm deep for 6 min. The outcome measured is the
time in seconds in which the mouse was immobile. The
latency of immobility was only assessed during the last
4 min of the test. The mouse was considered to be im-
mobile when it stopped moving, making only move-
ments necessary to keep its head above water.
Susceptibility to audiogenic seizures
Mice were placed in makrolon (polycarbonate) cages
(50 × 26 × 18 cm) and audiogenic seizures were induced
by vigorously scraping scissors across the metal grating of
the cage lid (which creates approximately a 100 dB sound).
This noise was generated for 20 s, or less if a tonic-clonic
seizure developed before that time. Susceptible mice
responded with wild running and leaping followed by a
tonic-clonic seizure, which typically lasted 10–20 s.
Western blot analysis and immunohistochemistry
Mice were sacrificed at 20–25 weeks of age, for subse-
quent analysis. For Western blots analysis, approximately
20 μg of protein lysate were loaded on 4–12% SDS-PAGE
gel (Bio-Rad) and transferred on nitrocellulose mem-
branes to be then incubated with anti-UBE3A antibody
(E8655 Sigma-Aldrich; 1:1000) and anti-actin antibody
(MAB1501R, Millipore; 1: 20000). Briefly, membranes
were blocked in 4% TBS milk solution for 1 h at room
temperature and incubated at 4 °C overnight, rotating end
over end, with the primary antibody dissolved in 2%
TBS-T milk solution. The day after membranes were
washed three times for 10min with TBS-T and incubated
with the secondary antibody, a fluorophore-conjugated
goat anti-mouse antibody (IR Dye 800CW, Westburg;
1:15000), dissolved in 2% TBS-T milk solution for 1 h. At
the end of the incubation, membranes were washed three
times for 10min with TBS and the resulting blots were an-
alyzed and quantified using a LI-COR Odyssey Scanner
and Odyssey 3.0 software.
For immunohistochemistry, mice were sedated with
0.15 ml Nembutal (60 mg/kg), transcardially perfused
and the brains were post-fixed with 4% paraformalde-
hyde in sodium phosphate buffer (PB) for 2 h. After in-
cubation in 10% sucrose (in 0.1M phosphate buffer)
overnight, brains were embedded in a sucrose/gelatin
mixture (10 and 12%, respectively). Brain sections were
cut on a microtome (SM2000R; Leica Microsystems,
Rijswijk, Netherlands) at a thickness of 40 μm and
treated with peroxidase (H2O2). The brain sections were
then washed in PBS and were incubated for 1 h in block-
ing buffer containing 10% horse serum, 0.5% Triton
X-100 in PBS. Subsequently, sections were incubated for
48–72 h in 2% normal horse serum, 0.5% Triton X-100
incubation buffer in PBS with primary antibody (mouse
anti-E6AP, clone 3E5 Sigma–Aldrich; 1:750). The sec-
ondary antibody (anti-mouse HRP, P0447 Dako; 1:200)
was detected by 3,3-diaminobenzidine (DAB) as the
chromogen, and DAB sections were analyzed and photo-
graphed using a Nanozoomer scanner.
Statistics
All data were statistically analyzed using IBM SPSS soft-
ware, and P values less than 0.05 were considered signifi-
cant. Statistical analysis was performed using univariate
ANOVA (Kruskal-Wallis statistic test when data were
non-normally distributed) or two way-repeated measures
ANOVA with Bonferroni’s and Dunnet/Mann-Whitney U
test post hoc comparison (see the Additional files for
more details).
Results
To elucidate the importance of continued UBE3A expres-
sion after early brain development, we took advantage of a
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conditional Ube3amflox/p+ mouse model [20] that enabled
us to delete the maternal Ube3a gene at any desired time
point. We first crossed female Ube3amflox/p+ mice with a
constitutive Cre-expressing mouse line [21]. This resulted
in full, early embryonic deletion of the maternal Ube3a al-
lele, and a consequent depletion of neuronal UBE3A pro-
tein expression in cortex, hippocampus, striatum and
cerebellum, similar to what has been observed for the
Ube3am−/p+ AS mouse model [18] (Fig. 1, Additional file 1:
Table S1, Additional file 2: Figure S1, Additional file 3:
Table S2). Next, we demonstrated that Creembryo;Ube3am-
flox/p+ faithfully recapitulate the phenotypes that we previ-
ously established to be present in three independent AS
mouse models [18, 19] (Fig. 2, Additional file 4: Table S3,
Additional file 5: Figure S2, Additional file 6: Table S4).
These behavioral phenotypes are in the domains of motor
function, anxiety and repetitive behaviors and were se-
lected to fulfill the following criteria: (1) large effect sizes
to allow multiple comparisons within and between co-
horts, (2) reproducible phenotypes across multiple AS
lines, (3) phenotypic penetrance in AS mice of different
ages and (4) tolerance of different experimenters.
Moreover, these tests can all be performed in a single
cohort of mice using a highly standardized (and opti-
mized) method [19].
Having established that Ube3amflox/p+ mice phenocopy
other AS lines tested in our behavioral test battery, we
investigated the importance of continued UBE3A ex-
pression in these behavioral paradigms, after early brain
development and into adulthood. To that end, we
crossed female Ube3amflox/p+ mice with a tamoxifen in-
ducible Cre line (CreERT) [22]. Ube3a gene deletion was
induced by IP injection of tamoxifen in juvenile mice at
3 weeks of age, and in adult mice at 12 weeks of age
(Fig. 2). Western blot analysis of mice sacrificed at ap-
proximately 20–25 weeks showed that overall UBE3A
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Fig. 1 Loss of UBE3A expression upon juvenile and adult Ube3a gene deletion. UBE3A Western blot analysis of wild-type mice and mice in which the
Ube3a gene deletion is induced at 3 weeks (‘juvenile deletion’) or at 12 weeks ‘adult deletion’. Mice were sacrificed between 22 and 25weeks of age.
The analysis shows that loss of UBE3A expression in the cortex (a), hippocampus (b), cerebellum (c) and striatum (d) of these mice is comparable to
mice in which the Ube3a gene is absent throughout development (‘embryonic deletion’) (N = 3 per genotype). Data shown are means with SEM (see
methods and Additional file 1 for statistical tests)
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protein levels in cortex, hippocampus and striatum of
CreERT;Ube3amflox/p+ mice closely resembled UBE3A
levels of brains in which Ube3a was deleted embryoni-
cally (Fig. 1; see also Additional file 7: Figure S3, Add-
itional file 8: Figure S4; Additional file 3: Table S2).
Immunohistochemistry confirmed tamoxifen-induced
Ube3a gene deletion throughout the brain (Add-
itional file 7: Figure S3, Additional file 8: Figure S4).
Having ascertained that tamoxifen efficiently deleted the
maternal Ube3a gene, we assessed the behavioral pheno-
types of these CreERT;Ube3amflox/p+ mice, minimally 7
weeks after gene deletion. This extended time period be-
tween gene deletion and testing not only allowed full
clearance of UBE3A protein, but also allowed the neurons
and neuronal networks to adapt to the loss of UBE3A ex-
pression, ensuring that any observed phenotypes were due
to permanent consequences of UBE3A loss.
Maternal Ube3a gene deletion in adult (12 week old)
mice resulted in impaired forced-swim test behavior. Sur-
prisingly however, performance in the accelerating
rotarod, open field, nest building and marble burying par-
adigms was not affected (Fig. 2; see also Additional file 5:
Figure S2). This indicates that these behaviors and their
supporting neural circuits do not depend on continued
UBE3A expression during adulthood [18]. Importantly,
the lack of phenotypic penetrance in these tests is not
caused by the age of testing (approximately 20–22 weeks),
since we have previously shown that these phenotypes are
still clearly present in AS mice aged 28 weeks [18]. More-
over, a retrospective analysis of several studies in our la-
boratory in which mice aged > 20 weeks were included,
showed a strong phenotype on all these tests (Add-
itional file 9: Figure S5).
For experiments in which Ube3a gene deletion was in-
duced in juvenile mice at 3 weeks of age, we chose again to
delay behavioral testing for a minimum of 7 weeks to allow
the brain to respond to the gene deletion. Consequently,
the age of testing was similar between juvenile deletion and
embryonic deletion mice (Creembryo;Ube3amflox/p+), allowing
for a direct comparison between these groups. Maternal
Ube3a gene deletion in juvenile mice resulted in a signifi-
cant impairment in the forced-swim test, highlighting once
more the necessity of continued UBE3A expression for nor-
mal performance on this test. In addition, these mice also
showed an impairment in the nest-building task. Since this
phenotype was not present in mice in which Ube3a gene
deletion was induced at 12 weeks of age, this result indi-
cates that the neuronal network supporting performance in
the nest-building task is not yet fully developed at 3 weeks
of age. Surprisingly, none of the other tests revealed
impairments, suggesting that by 3 weeks of age, the
brain has already developed to such an extent that
UBE3A protein is no longer required for normal per-
formance of most behaviors.
Most individuals with AS suffer from epilepsy. We have
previously shown that AS mice in the 129S2 background
exhibit exaggerated susceptibility to audiogenic seizures,
which can be suppressed by modulating CAMK2 activity
as well as by anti-epileptic drugs [18, 19, 25]. This pheno-
type is not age dependent as it is readily observed in AS
mice tested between 8 and 28weeks old [18, 19]. We
tested sensitivity to audiogenic seizures in 129S2- back-
crossed Ube3amflox/p+ mice in which the Ube3a gene was
deleted embryonically, at 3 weeks of age or in adulthood.
Early embryonic deletion of the Ube3a gene rendered all
(15/15) Creembryo;Ube3amflox/p+ mice susceptible to audio-
genic seizures. In contrast, neither juvenile (0/8) nor adult
Ube3a gene deletion (0/16) resulted in mice that were
sensitive to audiogenic seizures. This indicates that the
sensitivity to audiogenic seizure is exclusively dependent
on the presence or absence of UBE3A during early brain
development [18].
Discussion
The purpose of this study was to assess the role of the
Ube3a gene in the mature brain, with the specific goal of
gaining insight into whether UBE3A reinstatement therap-
ies must be sustained throughout life for maximal efficacy
in treating AS. In order to address this question, we took
advantage of the conditional Ube3amflox/p+ mouse model
[20], crossed with either a constitutive Cre-expressing
mouse line (Creembryo) [21] or with a tamoxifen-inducible
Cre line (CreERT) [22], to allow deletion of the Ube3a gene
at distinct times during brain development.
By deleting Ube3a during early embryogenesis, we
were able to reproduce all the behavioral deficits ob-
served in various AS mouse models, highlighting the
usefulness of this mouse model and the robustness of
(See figure on previous page.)
Fig. 2 Ube3a gene deletion in juvenile and adult mice does not recapitulate the phenotypes observed in embryonically deleted Ube3a mice. a
Schematic depicting Ube3a gene deletion at early embryonic age, juvenile age (3 weeks) and adult age (12 weeks). b–f Behavioral tasks
performed with Creembryo;Ube3amflox/p+ and CreERT;Ube3amflox/p+ mice. Juvenile and adult Ube3a gene deletion results in deficits in the forced
swim test. Asterisks indicate the effect of genotype. Wild-type (WT) mice in the Creembryo;Ube3amflox/p group represent combined data of Cre
positive and Cre negative animals (embryonic deletion: N for WT-Creembryo−/ WT-Creembryo+ / Ube3amflox/p+-Creembryo−/ Ube3amflox/p+-Creembryo+
mice = 15/group). Wild-type mice (WT) in the juvenile and adult-treated gene deletion group represent combined data of tamoxifen and vehicle-
treated wild-type mice (Juvenile deletion: N for WT-OIL/ WT-TAM / Ube3amflox/p+-VEH/ Ube3amflox/p+-TAM mice = 11, 13, 14, 16) (Adult deletion: N
for WT-OIL/ WT-TAM / Ube3amflox/p+-VEH/ Ube3amflox/p+-TAM mice = 15/group). Data shown are means with SEM (see methods and
Additional file 4 for statistical tests)
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these phenotypes [18, 19]. These results further confirm
the critical role of UBE3A during brain development, as we
established previously [18]. In contrast, we observed limited
phenotypic penetrance upon Ube3a deletion at 3 weeks or
12 weeks of age. We observed no deficits in motor coordin-
ation (rotarod), explorative behavior and anxiety (open
field), or repetitive behavior and anxiety (marble burying).
Nor did we evince a predisposition toward epilepsy as
assessed by the audiogenic seizure provocation test. These
results cannot be explained by the age of the mice at the
time of testing: juvenile deletion mice were the same age at
testing as Creembryo;Ube3amflox/p+ mice in which the gene
was deleted embryonically. Moreover, AS mice older than
20 weeks of age continue to exhibit robust phenotypes on
these tasks, as we demonstrated both here and in a previ-
ous study [18].
Our results corroborate findings from our reciprocal
Ube3a reinstatement studies [18], leading us to con-
clude that the circuits underlying these behaviors are
brought online during the perinatal period, and are
well established by weaning. In contrast, it appears
that circuits supporting nest-building behavior are not
yet fully mature at 3 weeks of age, since deletion of
Ube3a at this age (but not at 12 weeks) still results in
a significant deficit. Notably, irrespective of the age of
the mice, deletion of Ube3a always caused a deficit in
the forced swim test paradigm, suggesting that the
requisite circuits must sustain UBE3A expression for
normal performance on this task.
Limitations
Our study has several limitations. First of all, it is pos-
sible that tamoxifen-induced postnatal Ube3a gene dele-
tion does not occur in all cells. Our Western blot
analysis shows no significant differences between UBE3A
protein levels in mice with an embryonic Ube3a deletion
compared to mice with a postnatal deletion of Ube3a.
But this does not rule out the possibility that a small
percentage of neurons did not undergo Ube3a gene de-
letion following tamoxifen treatment, and that Ube3a
expression in a small subset of cells is sufficient to main-
tain normal behavioral function. A second limitation is
that we did not assess behaviors related to learning and
memory. Individuals with AS show severe intellectual
deficits, but as discussed previously [19], AS mouse
models do not show robust learning deficits in our
hands. Hence, we cannot exclude that normal learning
and memory requires UBE3A to be present at a time
when learning takes place. Finally, the face validity of
some of our behavioral tests is quite limited (e.g. marble
burying and nest building), as we do not know the
underlying circuits and the relevance of these circuits to
human AS phenotypes.
Conclusions
Our findings underscore the critical role of UBE3A for
normal brain development and suggest that most AS be-
havioral phenotypes arise from the absence of UBE3A
during embryonic or early postnatal development. Our
results also demonstrate that while expression of UBE3A
in the mature brain may not be required for the acquisi-
tion and performance of most tests investigated in this
study, certain behaviors do depend on continued UBE3A
expression. Hence, our study indicates that there is likely
to be a clinical benefit by having enduring UBE3A re-
instatement. Although we do not know how the first 3
weeks of postnatal brain development in mice translates
to human brain development, our results suggest that
even transient UBE3A reinstatement during a critical
window of early development is likely to prevent most
adverse Angelman syndrome phenotypes. Taken to-
gether these results emphasize the need to start Ube3a
gene reactivation therapies early in life, and to sustain
reactivation into adulthood for optimal effect.
Additional files
Additional file 1: Table S1. (referring to Fig. 1). Summary of the
statistical tests used for each Western blot analysis performed on each
experimental group. Statistical significance (2-sided, p < 0.05) is indicated
by green color. (XLS 31 kb)
Additional file 2: Figure S1. Deletion of UBE3A during embryogenesis.
A. Whole brain immunohistochemical stainings indicate reduced UBE3A
protein levels in Ube3aflox-Creembryo+ mice compared to Ube3aflox-
Creembryo– control mice. B. Ube3a gene deletion upon CRE activation
driven by the Cag promoter during embryogenesis. C. Western blot data
indicate reduced UBE3A protein levels in Ube3aflox-Creembryo+ mice
compared to control groups. Number of mice used for the Western blot
analysis is n = 3 per genotype. Data shown are mean (±SEM). See
Additional file 3 (Table S2) for statistical analysis and the sample sizes.
(PDF 85 kb)
Additional file 3: Table S2. (referring to Additional file 2: Figure S1,
Additional file 4: Figure S3, Additional file 8: Figure S4). Summary of the
statistical tests used for each Western blot analysis performed on each
experimental group. Statistical significance (2-sided, p < 0.05) is indicated
by green color. (XLS 30 kb)
Additional file 4: Table S3. (referring to Fig. 2). Summary of the
statistical tests used for behavioral paradigms performed on each
experimental group. Statistical significance (2-sided, p < 0.05) is indicated
by green color. The genotype is the independent variable of all the
statistical tests. (XLS 41 kb)
Additional file 5: Figure S2. Ube3a gene deletion in juvenile and adult
mice does not recapitulate the phenotypes observed in embryonically
deleted Ube3a mice. A. Schematic depicting Ube3a gene deletion at early
embryonic age, juvenile age (3 weeks) and adult age (12 weeks). B-F. Be-
havioral tasks performed with Creembryo;Ube3amflox/p+ (N for WT-Creembryo
−/ WT-Creembryo+ / Ube3amflox/p+-Creembryo−/ Ube3amflox/p+-Creembryo+
mice = 15/group) and CreERT;Ube3amflox/p+ mice (Juvenile deletion: N for
WT-OIL/ WT-TAM / Ube3amflox/p+-VEH/ Ube3amflox/p+-TAM mice = 11, 13,
14, 16; Adult deletion: N for WT-OIL/ WT-TAM / Ube3amflox/p+-VEH/
Ube3amflox/p+-TAM mice = 15/group) . Juvenile and adult Ube3a gene de-
letion results in deficits in the forced swim test. Asterisks indicate the ef-
fect of genotype. Data shown are means with SEM. See methods and
Additional file 6 for statistical tests and sample sizes. (PDF 401 kb)
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Additional file 6: Table S4. (referring to Additional file 5: Figure S2).
Summary of the statistical tests used for behavioral paradigms performed
on each experimental group. Statistical significance (2-sided, p < 0.05) is
indicated by green color. The genotype is the independent variable of all
the statistical tests. (XLS 41 kb)
Additional file 7: Figure S3. Deletion of UBE3A in young mice. A.
Immunohistochemical staining indicate reduced UBE3A protein levels in
Ube3aflox-TAM mice compared to Ube3aflox-VEH control group. B. Ube3a
gene deletion induced at 3 weeks of age upon CRE activation by
tamoxifen injection. C. Western blot data indicate reduced UBE3A protein
levels in Ube3aflox-Creembryo+ mice compared to control groups. Number
of mice used for the Western blot analysis is n = 3–4 per genotype. Data
shown are mean (±SEM). See Additional file 3: Table S2 for statistical
analysis and the sample sizes. (PDF 1445 kb)
Additional file 8: Figure S4. Deletion of UBE3A in adult mice. A.
Immunohistochemical stainings indicate reduced protein levels of BE3A
in Ube3aflox-TAM mice compared to Ube3aflox-VEH control group. B.
Ube3a gene deletion at 12 weeks of age upon CRE activation by
tamoxifen injection C. Western blot data indicate reduced UBE3A protein
levels in Ube3aflox-Creembryo+ mice compared to control groups. Number
of mice used for the Western blot analysis is n = 3/genotype. Data shown
are mean (±SEM). See Additional file 3: Table S2 for statistical analysis and
the sample sizes. (PDF 51 kb)
Additional file 9: Figure S5. Behavioral test battery in mice older than
20 weeks of age. A. Accelerating rotarod in wild-type (WT) and AS mice
(n = 51, 67). B. Nest building test in WT and AS mice (n = 39, 45). C. Open
field test in WT and AS mice (n = 36, 57). D. Marble burying test in WT
and AS mice (n = 47, 62). E. Forced swim test in WT and AS mice (n = 37,
60). All data represent mean ± SEM. A repeated measures ANOVA or t-test
(or Mann Whitney U test for nonparametric data) was used for statistical
comparison. All tests show a significance effect of genotype (***p < 0.001).
(PDF 142 kb)
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